ENGINEERED NANOBODIES WITH PROGRAMMABLE TARGET ANTIGEN PROTEOLYSIS (PTAP) FUSIONS REGULATE INTRACELLULAR ALPHA-SYNUCLEIN IN VITRO AND IN VIVO.
| العنوان: | ENGINEERED NANOBODIES WITH PROGRAMMABLE TARGET ANTIGEN PROTEOLYSIS (PTAP) FUSIONS REGULATE INTRACELLULAR ALPHA-SYNUCLEIN IN VITRO AND IN VIVO. |
|---|---|
| المؤلفون: | Chatterjee D; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612.; Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611., D'Brant LY; Regenerative Research Foundation, Neural Stem Cell Institute, Rensselaer, NY 12144., Hiller BM; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612., Marmion DJ; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612., Sandoval IM; Department of Translational Neuroscience, Barrow Neurological Institute, Phoenix, AZ 85013., Luk KC; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19147., Manfredsson FP; Department of Translational Neuroscience, Barrow Neurological Institute, Phoenix, AZ 85013., Messer A; Regenerative Research Foundation, Neural Stem Cell Institute, Rensselaer, NY 12144.; Department of Biomedical Sciences, University at Albany, Albany, NY 12208., Kordower JH; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612.; ASU-Banner Neurodegenerative Disease Research Center and School of Life Sciences, Arizona State University, Tempe, AZ 85281., Butler DC; Regenerative Research Foundation, Neural Stem Cell Institute, Rensselaer, NY 12144.; Department of Biomedical Sciences, University at Albany, Albany, NY 12208. |
| المصدر: | Research square [Res Sq] 2024 Mar 28. Date of Electronic Publication: 2024 Mar 28. |
| نوع المنشور: | Preprint |
| اللغة: | English |
| بيانات الدورية: | Country of Publication: United States NLM ID: 101768035 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: Res Sq Subsets: PubMed not MEDLINE |
| مستخلص: | Alpha-synuclein (αSyn) aggregation and the formation of Lewy pathology (LP) is a foundational pathophysiological phenomenon in synucleinopathies. Delivering therapeutic single-chain and single-domain antibodies that bind pathogenic targets can disrupt intracellular aggregation. The fusion of antibody fragments to a negatively-charged proteasomal targeting motif (PEST) creates bifunctional constructs that enhance both solubility and turnover. With sequence-specific point mutations of PEST sequences that modulate proteasomal degradation efficiency, we report the creation of Programmable Target Antigen Proteolysis (PTAP) technology that can provide graded control over the levels of target antigens. We have previously demonstrated our lead anti-αSyn intrabody, VH14-PEST, is capable of reducing the pathological burden of synucleinopathy in vitro and in vivo . Here, we report a family of fully humanized VH14-PTAP constructs for controllable, therapeutic targeting of intracellular α-Syn. In cells, we demonstrate successful target engagement and efficacy of VH14-hPEST intrabodies, and validate proof-of-principle in human cells using 3D human organoids derived from PD-patient induced pluripotent stem cells (iPSC). In two synuclein-based rat models, PTAP intrabodies attenuated nigral αSyn pathology, preserved nigrostriatal dopaminergic tone, and slowed the propagation of αSyn pathology. These data demonstrate the potency of intracellular αSyn targeting as a method to alleviate pathology and highlight the potential clinical utility of PTAP intrabodies. Competing Interests: Conflicts of Interest The authors A.M. and D.C.B are listed as inventors on a patent application (WO2022103977A1) filed by the Regenerative Research Foundation related to this work. J.H.K has received commercial support from Ryne Bio, Abbvie, Amydis, Inc., Biogen, Renovacor, Clintrex, Inhibikase Therapeutics, Inc., Mark Therapeutics, and Encora Therapeutics. |
| References: | Front Mol Neurosci. 2018 Feb 13;11:36. (PMID: 29497361) Science. 2010 Sep 24;329(5999):1663-7. (PMID: 20798282) MAbs. 2012 Nov-Dec;4(6):686-93. (PMID: 22929188) Autophagy. 2015;11(10):1803-20. (PMID: 26378614) Mov Disord. 2013 Jun;28(6):811-3. (PMID: 23457019) Neurobiol Aging. 2014 Sep;35(9):2180.e1-5. (PMID: 24746362) Pharmaceutics. 2022 Jul 05;14(7):. (PMID: 35890306) Science. 2020 Mar 27;367(6485):1428-1429. (PMID: 32217715) Science. 1997 Jun 27;276(5321):2045-7. (PMID: 9197268) Neurobiol Dis. 2019 May;125:146-153. (PMID: 30658149) Ageing Res Rev. 2019 Mar;50:89-101. (PMID: 30690184) Nat Nanotechnol. 2023 Oct;18(10):1241-1251. (PMID: 37430038) J Parkinsons Dis. 2018;8(2):303-322. (PMID: 29400668) Nat Commun. 2021 Feb 10;12(1):927. (PMID: 33568632) Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14524-9. (PMID: 12376616) Mol Ther. 2010 Aug;18(8):1450-7. (PMID: 20551914) Science. 2003 Oct 31;302(5646):841. (PMID: 14593171) Nat Genet. 2021 Mar;53(3):294-303. (PMID: 33589841) Mol Neurodegener. 2017 Jan 25;12(1):11. (PMID: 28122627) Hum Gene Ther Methods. 2016 Feb;27(1):32-45. (PMID: 26863210) Lancet. 2004 Sep 25-Oct 1;364(9440):1169-71. (PMID: 15451225) PLoS One. 2016 Nov 8;11(11):e0165964. (PMID: 27824888) EBioMedicine. 2020 Sep;59:102944. (PMID: 32810825) Front Neurol. 2022 May 09;13:852003. (PMID: 35614915) Lancet. 2004 Sep 25-Oct 1;364(9440):1167-9. (PMID: 15451224) Sci Rep. 2019 May 21;9(1):7567. (PMID: 31110191) Toxicon. 2010 Nov;56(6):990-8. (PMID: 20637220) J Clin Invest. 2015 Jul 1;125(7):2721-35. (PMID: 26075822) Neurology. 2013 Mar 12;80(11):1062-4. (PMID: 23427326) Neuron. 2013 Jun 5;78(5):785-98. (PMID: 23764284) Mov Disord. 2021 Jul;36(7):1624-1633. (PMID: 33617693) Biochem J. 2017 Jun 6;474(12):2039-2049. (PMID: 28495859) Cell. 2021 Aug 19;184(17):4547-4563.e17. (PMID: 34314701) Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):E8284-E8293. (PMID: 28900002) Nature. 1997 Aug 28;388(6645):839-40. (PMID: 9278044) Int J Mol Sci. 2023 Jul 03;24(13):. (PMID: 37446200) J Neuroinflammation. 2018 May 1;15(1):129. (PMID: 29716614) Neurobiol Dis. 2020 Feb;134:104619. (PMID: 31669671) Ann Neurosci. 2023 Jan;30(1):8-10. (PMID: 37313331) J Parkinsons Dis. 2017;7(s1):S51-S69. (PMID: 28282814) Neuron. 2000 Jan;25(1):239-52. (PMID: 10707987) Neurobiol Dis. 2021 Jan;148:105218. (PMID: 33296726) Cell Rep. 2016 Jun 14;15(11):2411-26. (PMID: 27264186) Ann Neurol. 2004 Feb;55(2):164-73. (PMID: 14755719) J Mol Biol. 2008 Mar 14;377(1):136-47. (PMID: 18237741) J Neurochem. 2016 Oct;139 Suppl 1:275-289. (PMID: 26617280) J Neurochem. 2019 Sep;150(5):475-486. (PMID: 31269263) EMBO J. 2003 Apr 1;22(7):1488-96. (PMID: 12660156) Nat Med. 2017 Feb 7;23(2):1-13. (PMID: 28170377) Lab Invest. 2019 Jul;99(7):971-981. (PMID: 30760864) Curr Biol. 2014 Oct 6;24(19):2319-26. (PMID: 25264250) Methods Mol Biol. 2019;1937:101-124. (PMID: 30706392) J Parkinsons Dis. 2022;12(4):1133-1153. (PMID: 35213388) Gene Ther. 2022 Jun;29(6):390-397. (PMID: 33753910) J Parkinsons Dis. 2020;10(2):573-590. (PMID: 32176654) Ann Neurol. 2013 Apr;73(4):459-71. (PMID: 23526723) Genes (Basel). 2021 Jun 21;12(6):. (PMID: 34205689) J Neurochem. 2019 Sep;150(5):577-590. (PMID: 31069800) Ann Clin Transl Neurol. 2016 Jun 16;3(8):588-606. (PMID: 27606342) Biomark Res. 2021 Dec 4;9(1):87. (PMID: 34863296) Nat Neurosci. 2019 Aug;22(8):1248-1257. (PMID: 31346295) EMBO J. 2007 Jan 10;26(1):123-31. (PMID: 17170706) Neurobiol Dis. 2019 Dec;132:104587. (PMID: 31454546) Science. 1989 Mar 17;243(4897):1493-5. (PMID: 2928784) Genes Dev. 2009 Mar 1;23(5):561-74. (PMID: 19270157) eNeuro. 2020 Aug 17;7(4):. (PMID: 32487763) Biophys J. 2010 Oct 6;99(7):2279-88. (PMID: 20923663) NPJ Parkinsons Dis. 2018 Aug 22;4:25. (PMID: 30155513) Neurosci Lett. 1998 Jul 31;251(3):205-8. (PMID: 9726379) Science. 2017 Dec 15;358(6369):1440-1443. (PMID: 29242346) Cell Stem Cell. 2008 Sep 11;3(3):346-353. (PMID: 18786421) J Biol Chem. 2019 Jul 5;294(27):10392-10406. (PMID: 31142553) |
| معلومات مُعتمدة: | R01 DK108798 United States DK NIDDK NIH HHS; T32 AG020506 United States AG NIA NIH HHS |
| تواريخ الأحداث: | Date Created: 20240408 Latest Revision: 20240425 |
| رمز التحديث: | 20240425 |
| مُعرف محوري في PubMed: | PMC10996777 |
| DOI: | 10.21203/rs.3.rs-4088206/v1 |
| PMID: | 38585932 |
| قاعدة البيانات: | MEDLINE |
| DOI: | 10.21203/rs.3.rs-4088206/v1 |
|---|